NCT05387759View on ClinicalTrials.gov

A Thorough QT Study of Aticaprant (JNJ-67953964) in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 30, 2022

Primary Completion Date

October 4, 2022

Study Completion Date

October 4, 2022

Conditions
Healthy
Interventions
DRUG

Aticaprant Supratherapeutic Dose

Aticaprant supratherapeutic dose capsule will be administered orally.

DRUG

Aticaprant Therapeutic Dose

Aticaprant therapeutic dose capsule will be administered orally.

DRUG

Placebo

Placebo will be administered orally.

DRUG

Moxifloxacin

Moxifloxacin capsule will be administered orally.

Trial Locations (1)

2170

Clinical Pharmacology Unit, Merksem

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY